In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. 
Here are the trials we discussed: 
1. IWG 2019 response criteria

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 

2. MEDALIST trial: Luspatercept

https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 

3. COMMANDS trial : Luspatercept 

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstract

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract 

4. IMerge trial: Imetelstat 

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract